On a U-100 syringe scale, 50 represents 0.5 mL. The medication amount in that volume depends on the liquid concentration. A scale reading alone does not identify a milligram amount.
Convert volume first, then medication amount
For this scale, volume in mL = scale reading ÷ 100. Then medication amount in mg = volume in mL × concentration in mg/mL. These examples illustrate the equation. Each concentration is an input to the calculation.
| Example concentration | Volume at 50 on U-100 | Amount in that volume |
|---|---|---|
| 2.5 mg/mL | 0.5 mL | 1.25 mg |
| 5 mg/mL | 0.5 mL | 2.5 mg |
| 10 mg/mL | 0.5 mL | 5 mg |
| 20 mg/mL | 0.5 mL | 10 mg |
Keep the vial amount separate from concentration
"10 mg in the vial" identifies an amount. "10 mg/mL" identifies a concentration. Those phrases look similar but answer different questions. A total vial amount needs a corresponding total liquid volume before concentration can be calculated.
Compare two labels without changing the scale reading
In the examples above, the volume remains 0.5 mL while the concentration changes. That is why the milligram amounts differ. Reusing the same scale reading with a different concentration does not preserve the medication amount.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The equation uses amount and volume rather than a medication name. The medication name still matters for identifying the exact product and its concentration, but it cannot replace the concentration field in the calculation.
FAQ
Does 50 units always mean 5 mg?
No. It gives 5 mg only in the example using a U-100 scale and 10 mg/mL concentration.
Does this apply to every syringe?
The first step is specific to a U-100 scale. Other scales and pen settings require their own interpretation.
How can I check an example?
Multiply the stated concentration by the calculated volume. The mg/mL and mL units cancel to leave mg.
Related conversion guide
Convert a 2.5 mg amount to volume at different concentrations.
Sources
When 50 units is the wrong volume to draw
There are three situations where drawing 50 units is incorrect, even if your math says it should be 50 units:
Situation 1: Your syringe barrel is too small. If you're using a 0.3 mL barrel syringe (30-unit capacity) or a 0.5 mL barrel syringe (50-unit capacity), you can't draw more than the barrel holds. A 0.5 mL syringe can draw exactly 50 units, but not 51. If your dose calculates to more than your syringe's capacity, you need a larger barrel or a higher-concentration vial.
Situation 2: The vial doesn't have enough liquid left. Multi-dose vials contain enough medication for multiple injections, but not infinite injections. If you're drawing the last dose from a vial and there's only 0.3 mL left, you can't draw 0.5 mL. You'll need to open a new vial or draw a partial dose and supplement with the new vial. Never combine liquid from two vials in the same syringe unless your provider has specifically instructed you to do so.
Situation 3: Your dose falls between unit markings. Some doses don't land on a whole-unit line. For example, 7.5 mg at 20 mg/mL is (7.5 ÷ 20) × 100 = 37.5 units. A 1 mL or 0.5 mL syringe marked in 1-unit increments doesn't have a 37.5 line. A 0.3 mL U-100 barrel holds at most 30 on the scale, so it cannot represent a 37.5-unit volume even if it has half-unit increments. Ask your provider or pharmacist whether the calculation can be represented by the specific device.
Rounding rules: there is no published rounding tolerance for compounded GLP-1s, so ask your provider or pharmacist rather than deciding alone. A useful sanity check is that the FDA-approved brand doses come in fixed steps: tirzepatide 2.5, 5, 7.5, 10, 12.5 and 15 mg (Zepbound label, revised 08/2026) and semaglutide 0.25, 0.5, 1 and 2 mg for Ozempic, up to 2.4 mg for Wegovy. An earlier version of this page said a 2% to 5% variation was clinically insignificant; that was an unsourced judgment and has been removed.
The decision tree: should you round, split, or call?
Use this flowchart when your calculated unit count doesn't match a syringe marking:
If the difference is 0.5 units or less: A small difference in scale values does not establish an acceptable rounding rule; confirm with your provider. At 10 mg/mL, 24.5 corresponds to 2.45 mg, while 24 and 25 correspond to 2.4 and 2.5 mg.
If the difference is 1 to 2 units: Ask your provider or pharmacist before rounding. At low doses a 1-unit change is a larger share of the total dose, and no published tolerance exists for compounded GLP-1s.
If the difference is more than 2 units: Don't round. Either request a different concentration from your pharmacy, ask about a device whose capacity and increments represent the calculated volume, or ask your provider if the dose can be adjusted to land on a whole-unit marking.
If your dose requires more volume than your syringe holds: Request a higher-concentration vial from your pharmacy. Example: if you're prescribed 10 mg and your vial is 5 mg/mL, you'd need to draw 200 units (2 mL). A standard 1 mL syringe can't hold this. Switching to a 20 mg/mL vial reduces the draw to 50 units (0.5 mL).
If you're unsure: Call your provider or the compounding pharmacy. Both have dosing calculators and can confirm the correct unit count in under a minute. Don't guess.
Storage and stability after drawing a dose
Once you've drawn medication into a syringe, the clock starts on stability. Compounded semaglutide and tirzepatide are peptides, which are sensitive to temperature, light, and contamination.
Immediate injection (recommended): inject within 5 minutes of drawing. This minimizes exposure to room temperature and light.
Short-term hold (acceptable): if you need to draw the dose in advance (e.g., traveling, injecting at a specific time), store the filled syringe in the refrigerator (36 to 46°F) with the needle capped, and only if your pharmacy's instructions allow pre-drawing. Do not freeze.
Room-temperature hold (not recommended): GLP-1 peptides degrade faster at room temperature. Stability data for compounded products come from the dispensing pharmacy's beyond-use date and storage instructions, not from published studies, so follow them. Correction, September 2026: an earlier version of this page cited a 2023 stability study with potency percentages; no such study could be found and it has been removed.
Light exposure: peptides are photosensitive. If you're storing a filled syringe, wrap it in aluminum foil or place it in an opaque container.
Contamination risk: once a needle has punctured a vial, the sterility of the remaining liquid depends on the preservative (usually benzyl alcohol in multi-dose vials). Most compounding pharmacies label multi-dose vials "use within 28 days of first puncture." Single-dose vials without preservative should be used immediately and discarded after one draw.
What FDA says about dosing errors with compounded GLP-1s (as of May 31, 2026)
FDA's page on unapproved GLP-1 drugs used for weight loss reports that it has received adverse event reports of dosing errors with compounded semaglutide and tirzepatide, including patients who measured the wrong amount because of confusion between units, milliliters and milligrams, in some cases taking several times the intended dose. As of May 31, 2026, FDA counted 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide. FDA also declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025. Correction, September 2026: an earlier version of this page stated that more than 60% of compounded GLP-1 dosing errors stem from concentration confusion; that figure could not be traced to any published source and has been removed. FDA describes the problem qualitatively and does not publish a percentage.
Corrections, September 2026
Correction, September 2026: an earlier version of this page cited studies by Chen (2023), Martinez (2024), Park (2023), Patel (2024) and Thompson (2025) and an FDA 2020 guidance on insulin syringes, none of which could be found; all have been removed from the text and the source list, along with an unverified ISO 8537 tolerance figure, an invented 60% dosing-error statistic, and unsourced judgments that a 2 to 5% rounding variation or a 20% overdose was clinically insignificant. The arithmetic on this page has been rechecked and is unchanged: mg = (units divided by 100) multiplied by the concentration in mg/mL, so 50 units is 0.5 mL and equals 1.25 mg at 2.5 mg/mL, 2.5 mg at 5 mg/mL, 5 mg at 10 mg/mL and 10 mg at 20 mg/mL. The statement on syringe prescriptions now matches our Zepbound needle guide: rules vary by state and pharmacy.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →